Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

The Urologic clinics of North America·2026
Same author

Metachronous contralateral recurrence in upper tract urothelial carcinoma: a multi-institutional competing-risks analysis from the ROBUUST 3.0 registry.

Urology practice·2026
Same author

Insulin Pathway Changes in Localized Prostate Cancer: A Multi-Institutional Analysis.

Cancers·2026
Same author

Time toxicity of intravesical BCG versus sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.

BJUI compass·2026
Same author

Cost-Effectiveness of Immune Checkpoint Inhibitor Therapy plus BCG for High-Risk Non-Muscle-Invasive Bladder Cancer: Analyses of CREST, POTOMAC, and ALBAN.

The Journal of urology·2026
Same author

Tumor-informed ctDNA surveillance after radical nephrectomy and level IV IVC thrombectomy for clear cell renal cell carcinoma: Early detection of molecular residual disease.

Urology case reports·2026
Same journal

Normal Reference Values for Testicular Volume in Adult Somali Men: A Retrospective Study.

Research and reports in urology·2026
Same journal

Vacuum-Assisted Mini-PCNL is Associated with Lower Postoperative SIRS: A Real-World Cohort Study.

Research and reports in urology·2026
Same journal

Assessing the Knowledge and Awareness of Urinary Incontinence Among Urogynecology Clinic Patients in Jordan: A Cross-Sectional Study.

Research and reports in urology·2026
Same journal

Early Progressive Disease During Nivolumab Plus Ipilimumab Therapy Predicts Poor Survival in Japanese Patients with Advanced Renal Cell Carcinoma: A Single-Center 12-Week Landmark Study.

Research and reports in urology·2026
Same journal

Hydrocelectomy Complication Rates in the United States.

Research and reports in urology·2026
Same journal

Artificial Intelligence as a Diagnostic Tool for Benign Prostatic Hyperplasia (BPH): A Narrative Review.

Research and reports in urology·2026
See all related articles

Related Experiment Video

Updated: May 10, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.2K

Sequential Intravesical Gemcitabine and Docetaxel for Non-Muscle Invasive Bladder Cancer: A Narrative Review Across

Mahdi Hemmati Ghavshough1, Melinda Z Fu1, Raeesa Islam1

  • 1Department of Urology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Research and Reports in Urology
|March 30, 2026
PubMed
Summary
This summary is machine-generated.

Sequential intravesical gemcitabine and docetaxel (Gem/Doce) shows promise for non-muscle-invasive bladder cancer (NMIBC). This bladder-sparing treatment offers good outcomes and safety, especially for BCG-unresponsive NMIBC.

Keywords:
docetaxelgemcitabinenaïverefractorytreatment failureuntreatedurinary bladder neoplasms

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Related Experiment Videos

Last Updated: May 10, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.2K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Area of Science:

  • Urology
  • Oncology
  • Clinical Research

Background:

  • Non-muscle-invasive bladder cancer (NMIBC) is the most common form of bladder cancer, with high recurrence and progression rates.
  • Intravesical Bacillus Calmette-Guérin (BCG) is the standard for high-risk NMIBC, but alternatives are needed due to intolerance, failure, and shortages.

Purpose of the Study:

  • To review and critically evaluate clinical evidence for sequential intravesical gemcitabine and docetaxel (Gem/Doce) in NMIBC.
  • To assess Gem/Doce's efficacy and safety across various NMIBC clinical contexts.

Main Methods:

  • A narrative review of published clinical studies on sequential intravesical Gem/Doce in NMIBC patients.
  • Analysis of oncologic outcomes (recurrence-free survival, progression, cystectomy) and adverse events.
  • Description of emerging biomarker-based risk stratification approaches.

Main Results:

  • Gem/Doce demonstrates favorable recurrence-free survival and acceptable safety in BCG-unresponsive or previously treated high-risk NMIBC.
  • Low rates of progression and cystectomy are reported, with uncommon treatment discontinuation due to toxicity.
  • Exploratory studies on AI-assisted biomarkers for risk stratification require further validation.

Conclusions:

  • Sequential intravesical Gem/Doce is a well-tolerated, bladder-sparing option with encouraging outcomes for recurrent or BCG-unresponsive NMIBC.
  • Further prospective randomized trials are needed to confirm Gem/Doce's role as a first-line therapy in treatment-naïve NMIBC.